With a market capitalization (market cap) of $2.25B — a measure of how much the company is worth — Harmony Biosciences Holdings, Inc. is the 2017th most valuable company in Healthcare as of August 18, 2026. Shares trade at $38.83, up +1.81% on the day.
of 2,587
price ÷ annual EPS
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.
Visit websiteAs of August 18, 2026, Harmony Biosciences Holdings, Inc. (HRMY) is worth $2.25B — this is its market capitalization, the total value of all its outstanding shares.
Harmony Biosciences Holdings, Inc.’s market cap is $2.25B, which ranks it #2017 among the most valuable companies in the Healthcare sector tracked on MarketCapLens.
Harmony Biosciences Holdings, Inc. (HRMY) shares trade at $38.83, up 1.81% on the day, as of August 18, 2026.
Fundamentals are annual. Figures labeled with their fiscal year.
FY 2025
Harmony Biosciences Holdings, Inc. trades at a price-to-earnings (P/E) ratio of 14.1, based on its latest share price and annual earnings per share.